Magnesium sulfate for neuroprotection: now or not yet

        THE ISSUE: Cerebral palsy is infrequent, but causes devastating neurologic consequences in preterm infants. Three recent randomized trials and several metaanalyses have evaluated the role of antenatal magnesium sulfate for neuroprotection in patients at risk for early preterm delivery. Despite the recommendations from the metaanalyses, there is uncertainty about whether to treat or who to treat, if any, with magnesium sulfate.
        To read this article in full you will need to make a payment

        Purchase one-time access:

        Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
        One-time access price info
        • For academic or personal research use, select 'Academic and Personal'
        • For corporate R&D use, select 'Corporate R&D Professionals'


        Subscribe to American Journal of Obstetrics & Gynecology
        Already a print subscriber? Claim online access
        Already an online subscriber? Sign in
        Institutional Access: Sign in to ScienceDirect